Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Jean-Philippe

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Current HIV Research|August 13, 2025
Integration of Preclinical and Clinical Vaccine Safety and Immunogenicity Testing for Development of a Pediatric HIV Vaccine to Achieve Protective HIV Immunity Prior to AdolescenceGenevieve G Fouda, Anjali Singh, Ashley Nelson, et al.
The Lancet. HIV|July 17, 2019
Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research prioritiesSharon Nachman, Claire L Townsend, Elaine J Abrams, et al.
The Journal of Pediatrics|May 25, 2012
Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virusJorge Lujan-Zilbermann, Meredith G Warshaw, Paige L Williams, et al.
The Pediatric Infectious Disease Journal|October 12, 2011
Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected childrenGeorge K Siberry, Meredith G Warshaw, Paige L Williams, et al.
Frontiers in Pediatrics|August 22, 2022
Antiretroviral choice and severe disease predict poorer neuropsychological outcomes in HIV+ children from AfricaLee Fairlie, Miriam Chernoff, Mark F Cotton, et al.
The Journal of Infectious Diseases|January 25, 2002
Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baselineDivna Nikolic-Djokic, Shaffiq Essajee, Mona Rigaud, et al.
BMC Pregnancy and Childbirth|January 17, 2023
Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trialPatricia Mandima, Kristin Baltrusaitis, Grace Montepiedra, et al.
The Pediatric Infectious Disease Journal|May 1, 2010
Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescentsGeorge K Siberry, Paige L Williams, Jorge Lujan-Zilbermann, et al.
Open Forum Infectious Diseases|November 29, 2024
Infectivity and Immunogenicity of Live-Attenuated Respiratory Syncytial Virus Vaccines in Human Immunodeficiency Virus-Exposed Uninfected ChildrenMatthew S Kelly, Coleen K Cunningham, Elizabeth J McFarland, et al.
AIDS (London, England)|May 23, 2012
Early antiretroviral therapy improves neurodevelopmental outcomes in infantsBarbara Laughton, Morna Cornell, Debbie Grove, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Current HIV Research|August 13, 2025
Integration of Preclinical and Clinical Vaccine Safety and Immunogenicity Testing for Development of a Pediatric HIV Vaccine to Achieve Protective HIV Immunity Prior to AdolescenceGenevieve G Fouda, Anjali Singh, Ashley Nelson, et al.
The Lancet. HIV|July 17, 2019
Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research prioritiesSharon Nachman, Claire L Townsend, Elaine J Abrams, et al.
The Journal of Pediatrics|May 25, 2012
Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virusJorge Lujan-Zilbermann, Meredith G Warshaw, Paige L Williams, et al.
The Pediatric Infectious Disease Journal|October 12, 2011
Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected childrenGeorge K Siberry, Meredith G Warshaw, Paige L Williams, et al.
Frontiers in Pediatrics|August 22, 2022
Antiretroviral choice and severe disease predict poorer neuropsychological outcomes in HIV+ children from AfricaLee Fairlie, Miriam Chernoff, Mark F Cotton, et al.
The Journal of Infectious Diseases|January 25, 2002
Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baselineDivna Nikolic-Djokic, Shaffiq Essajee, Mona Rigaud, et al.
BMC Pregnancy and Childbirth|January 17, 2023
Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trialPatricia Mandima, Kristin Baltrusaitis, Grace Montepiedra, et al.
The Pediatric Infectious Disease Journal|May 1, 2010
Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescentsGeorge K Siberry, Paige L Williams, Jorge Lujan-Zilbermann, et al.
Open Forum Infectious Diseases|November 29, 2024
Infectivity and Immunogenicity of Live-Attenuated Respiratory Syncytial Virus Vaccines in Human Immunodeficiency Virus-Exposed Uninfected ChildrenMatthew S Kelly, Coleen K Cunningham, Elizabeth J McFarland, et al.
AIDS (London, England)|May 23, 2012
Early antiretroviral therapy improves neurodevelopmental outcomes in infantsBarbara Laughton, Morna Cornell, Debbie Grove, et al.
Pageof 9